Page 7 - Mark Cragg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark cragg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Cragg Today - Breaking & Trending Today

New analysis method for predicting the risks and effects of immunotherapy

E-Mail
IMAGE: Sara Mangso is an Associate senior lecturer/Assistant Professor at the Department of Pharmaceutical Biosciences, Uppsala University
view more
Credit: Mikael Wallerstedt
In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
Immunotherapy - utilising the body s own immune system to combat tumour cells - is an area in which rapid progress is being made. Many new treatments are helping to increase survival rates among cancer patients, but more effective tools are still needed to predict how these drugs will affect an individual s immune system. In a new study at Uppsala University, researchers compared what happens when Ritux ....

Uppsala Lan , Mattias Mattsson , Sara Mangsbo , Mark Cragg , Uppsala University , Professor Of Experimental Cancer Research , University Of Southampton , Swedish Research Council , Department Of Pharmaceutical Biosciences , Uppsala University Hospital Haematology Clinic , Cytokine Release Syndrome , Experimental Cancer Research , குறி க்ர்யாக் , ப்ரொஃபெஸர் ஆஃப் சோதனை புற்றுநோய் ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் சவுத்தாம்ப்டன் , ஸ்விட்ச் ஆராய்ச்சி சபை , துறை ஆஃப் மருந்து உயிர் அறிவியல் , சோதனை புற்றுநோய் ஆராய்ச்சி ,

New analysis method could pave the way for important breakthroughs in immunotherapy

New analysis method could pave the way for important breakthroughs in immunotherapy
In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
Immunotherapy - utilizing the body s own immune system to combat tumor cells - is an area in which rapid progress is being made. Many new treatments are helping to increase survival rates among cancer patients, but more effective tools are still needed to predict how these drugs will affect an individual s immune system. In a new study at Uppsala University, researchers compared what happens when Rituximab monoclonal antibodies interact with the blood of healthy individuals and of patients with the disease that the monoclonal ....

Uppsala Lan , Mattias Mattsson , Sara Mangsbo , Mark Cragg , Emily Henderson , Uppsala University , Professor Of Experimental Cancer Research , University Of Southampton , Swedish Research Council , Department Of Pharmaceutical Biosciences , Uppsala University Hospital Hematology Clinic , Cytokine Release Syndrome , Pharmaceutical Biosciences , Experimental Cancer Research , குறி க்ர்யாக் , எமிலி ஹென்டர்சன் , ப்ரொஃபெஸர் ஆஃப் சோதனை புற்றுநோய் ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் சவுத்தாம்ப்டன் , ஸ்விட்ச் ஆராய்ச்சி சபை , துறை ஆஃப் மருந்து உயிர் அறிவியல் , மருந்து உயிர் அறிவியல் , சோதனை புற்றுநோய் ஆராய்ச்சி ,